芳香化酶抑制剂在儿科领域应用研究进展

Research progress of aromatase inhibitors in children

芳香化酶抑制剂在儿科内分泌疾病治疗中应用较为广泛。其中,作为第三代芳香化酶抑制剂的来曲唑(letrozole)及阿那曲唑(anastrozole)与芳香化酶可逆结合后,可抑制雄激素向雌激素转化,降低雌激素水平。其可辅助治疗特发性身材矮小、青春期生长激素缺乏症、体质性青春发育延迟的矮小患儿,延迟其骨骺闭合、促进长高,提高其生活质量。与生长激素联合应用促长高效果更明显,又可用于性发育异常的治疗等。但芳香化酶抑制剂对患儿椎体畸形、认知发展及成年后睾丸体积无明显影响。本文就芳香化酶抑制剂在儿科领域应用研究进展作一综述。

Aromatase inhibitors are widely used in pediatric endocrine diseases.Among them,letrozole and anastrozole,as the third generation aromatase inhibitors,can inhibit the conversion of androgen to estrogen and reduce the level of estrogen after reversibly combining with aromatase.It can assist the treatment of idiopathic short stature,adolescent growth hormone deficiency,constitutional delay of puberty,delay of epiphysis closure.It can also promote their growth and improve their quality of life.Combined with growth hormone,it has more obvious effect on promoting growth and height,and can also be used in the treatment of sexual dysplasia.However,aromatase inhibitors have no significant effect for children on vertebral deformity,cognitive development and testicular volume of adult.This paper reviewed the application of aromatase inhibitors in pediatrics.